✦ LIBER ✦

Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy

✍ Scribed by F.M. Russell; P.V. Licciardi; A. Balloch; V. Biaukula; L. Tikoduadua; J.R. Carapetis; J. Nelson; A.W.J. Jenney; L. Waqatakirewa; S. Colquhoun; Y.B. Cheung; M.L.K. Tang; E.K. Mulholland

Book ID: 116962492
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 418 KB
Volume: 28
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2010.02.065

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immunogenicity following one, two, or th

Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine

✍ F.M. Russell; A. Balloch; M.L.K. Tang; J.R. Carapetis; P. Licciardi; J. Nelson; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 383 KB

Opsonophagocytic activity following a re

Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age

✍ F.M. Russell; J.R. Carapetis; R.L. Burton; J. Lin; P.V. Licciardi; A. Balloch; L 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 240 KB

The Immunogenicity of 7‐Valent Pneumococ

The Immunogenicity of 7‐Valent Pneumococcal Conjugate Vaccine versus 23‐Valent Polysaccharide Vaccine in Adults Aged 50–80 Years

✍ Goldblatt, David; Southern, Jo; Andrews, Nick; Ashton, Lindsey; Burbidge, Polly; 📂 Article 📅 2009 🏛 University of Chicago Press 🌐 English ⚖ 309 KB

Serotype-specific avidity is achieved fo

Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months

✍ F.M. Russell; A. Balloch; P.V. Licciardi; J.R. Carapetis; L. Tikoduadua; L. Waqa 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 601 KB

PIN64 Assessing the Cost-Effectiveness (

PIN64 Assessing the Cost-Effectiveness (CE) of Vaccinating the Elderly and at-Risk Adults With the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) or no Vaccination (NoVac) in the UK

✍ Y. Jiang; A. Gauthier; S.T. Keeping; S.M. Carroll 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PIN19 A Budget Impact (BI) Analysis of V

PIN19 A Budget Impact (BI) Analysis of Vaccinating the Elderly and At-Risk Adults With the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) Compared to No Vaccination (NoVac) or 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in the UK

✍ Y. Jiang; A. Gauthier; S.T. Keeping; S.M. Carroll 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB